This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Intravenous Weekly Topotecan In Subjects With Recurrent Or Persistent Endometrial Cancer

This study has been completed.
Information provided by (Responsible Party):
GlaxoSmithKline Identifier:
First received: December 20, 2005
Last updated: June 28, 2012
Last verified: June 2012
Results First Received: December 5, 2008  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Single Group Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Conditions: Neoplasms, Endometrial
Endometrial Cancer
Intervention: Drug: topotecan

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
Topotecan Hydrochloride Subjects received IV weekly Topotecan administered at either 2.5 mg/m2(if the subject had prior pelvic radiotherapy) or 3.0 mg/m2 on Days 1, 8 and 15(+ or - 2 days) every 28 days.

Participant Flow:   Overall Study
    Topotecan Hydrochloride
Sponsor Terminated Study                9 
Protocol Violation                1 
Other (Disease Progression)                1 

  Baseline Characteristics

  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Best Overall Response   [ Time Frame: Week 0 to Week 98 when endpoints were met ]

2.  Secondary:   Time to Progression   [ Time Frame: Week 0 to Week 19 when endpoints were met ]

3.  Secondary:   Overall Survival   [ Time Frame: Week 0 to Week 98 ]

4.  Secondary:   Response Duration   [ Time Frame: Week 0 to week 98 ]

5.  Secondary:   Time to Response   [ Time Frame: Week 0 to week 98 ]

6.  Secondary:   Safety and Tolerability as Summarized Through Adverse Event Reporting   [ Time Frame: Week 0 to week 98 ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
As there was only 1 responder, time to response, and duration of response were not calculated.

  More Information